In patients with relapsed marginal zone lymphoma (MZL), the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death relative to rituximab alone in a subset analysis of the phase 3 CHRONOS trial.
The large clinical benefit supports the combination of copanlisib (Aliqopa, Bayer) and rituximab as “a new therapeutic strategy” in relapsed MZL, according to investigator Muhit Özcan, MD, a clinician and researcher in the Department of